FAPI and FDG PET/MRI in Diagnosis and Therapy Prediction of Bladder Cancer

Launched by FIRST AFFILIATED HOSPITAL OF FUJIAN MEDICAL UNIVERSITY · May 15, 2024

Keywords

ClinConnect Summary

This clinical trial is studying new imaging techniques called FAPI PET/MRI and FDG PET/MRI, along with standard MRI, to help diagnose muscle-invasive bladder cancer (MIBC) and predict how well patients will respond to a specific treatment called neoadjuvant therapy. The goal is to improve the way doctors can adjust treatment plans to ensure that MIBC patients receive the most effective care possible.

To participate in this trial, individuals must be between 65 and 74 years old and suspected of having MIBC or already diagnosed with it. Participants will need to undergo FAPI PET/MRI, FDG PET/MRI, and MRI scans, and they should have complete medical and lab records. Those with other cancers, certain health issues, or incomplete medical data may not be eligible. By joining this trial, participants can expect to contribute to important research that may lead to better diagnosis and treatment strategies for bladder cancer in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Inclusion criteria for MIBC diagnostic studies
• • 1. Patients with suspected muscle-invasive bladder cancer;
• • 2. Completion of FAPI PET/MRI, FDG PET/MRI and MRI;
• • 3. Complete clinical laboratory and pathological data.
• • Inclusion criteria for MIBC neoadjuvant therapy efficacy evaluation study
• • 1. Patients diagnosed with muscle invasive bladder cancer;
• • 2. Completion of FAPI PET/MRI, FDG PET/MRI, and MRI before neoadjuvant therapy;
• • 3. Complete clinical laboratory and pathological data.
• Exclusion Criteria:
• • Exclusion criteria for MIBC diagnostic study
• • 1. Combined with other malignant tumors;
• • 2. Not receiving surgical treatment;
• • 3. Receiving neoadjuvant therapy before surgery;
• • 4. Previous allergy to contrast components or similar components;
• • 5. Serious organ function abnormalities, such as heart, lung, liver, kidney function serious abnormalities;
• • 6. Incomplete clinicopathological data
• • Exclusion criteria of MIBC neoadjuvant therapy efficacy evaluation study
• • 1. Combination of other malignant tumors;
• • 2. FAPI PET/MRI, FDG PET/MRI and MRI were not completed after neoadjuvant therapy;
• • 3. Prior hypersensitivity to contrast components or similar components;
• • 4. Serious organ function abnormalities, such as serious abnormalities of heart, lung, liver and kidney function;
• • 5. Incomplete clinicopathological data.